Holen Sie sich die Stockscreener-App
39.07
4.46%
-1.75
Schlusskurs vom Vortag:
$40.82
Offen:
$40.78
24-Stunden-Volumen:
484.68K
Relative Volume:
0.56
Marktkapitalisierung:
$1.80B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-146.66M
KGV:
-14.19
EPS:
-2.7541
Netto-Cashflow:
$-133.21M
1W Leistung:
-0.28%
1M Leistung:
-10.10%
6M Leistung:
-2.82%
1J Leistung:
-21.92%
1-Tages-Spanne:
$38.75
$40.90
1-Wochen-Bereich:
$38.75
$42.29
52-Wochen-Spanne:
$26.20
$63.50
Apogee Therapeutics Inc Stock (APGE) Company Profile
Firmenname
Apogee Therapeutics Inc
Sektor
Branche
Telefon
650-394-5230
Adresse
221 CRESCENT ST., WALTHAM
Vergleichen Sie APGE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
39.08 | 2.38B | 0 | -146.66M | -133.21M | -2.7541 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.34 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.15 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.67 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
595.28 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.86 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-07 | Bestätigt | BTIG Research | Buy |
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2024-11-25 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-05-10 | Eingeleitet | BofA Securities | Buy |
| 2023-12-20 | Eingeleitet | BTIG Research | Buy |
| 2023-08-08 | Eingeleitet | Guggenheim | Buy |
| 2023-08-08 | Eingeleitet | Jefferies | Buy |
| 2023-08-08 | Eingeleitet | Stifel | Buy |
| 2023-08-08 | Eingeleitet | TD Cowen | Outperform |
| 2023-08-08 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Apogee Therapeutics Inc Aktie (APGE) Neueste Nachrichten
Should I hold or sell Apogee Therapeutics Inc. stock in 2025Triple-digit growth rates - jammulinksnews.com
Is Apogee Therapeutics Inc. stock overvalued or undervaluedFind the best stocks for sustainable growth - jammulinksnews.com
What makes Apogee Therapeutics Inc. stock price move sharplySolid Return Trade Selections - Newser
Intrinsic Value of Apogee Therapeutics Inc. Stock: Is It Undervalued or OvervaluedFree Elite Traders Group - Newser
What analysts say about Apogee Therapeutics Inc. stockOver 200% growth - PrintWeekIndia
What drives Apogee Therapeutics Inc. stock priceDynamic growth stocks - Autocar Professional
Apogee Therapeutics Inc. Stock Analysis and ForecastBreakthrough capital growth - Autocar Professional
What makes Apogee Therapeutics Inc. stock attractive to long term investorsDynamic growth stocks - jammulinksnews.com
Is Apogee Therapeutics Inc. a good long term investmentOutstanding capital returns - jammulinksnews.com
InvestingPro Fair Value model captures 43% downside in Apogee Therapeutics By Investing.com - Investing.com Canada
Teacher Retirement System of Texas Sells 629 Shares of Apogee Therapeutics Inc. (NASDAQ:APGE) - Defense World
BTIG Raises PT on Apogee Therapeutics (APGE) to $115 From $100, Keeps a Buy Rating - MSN
Will Apogee Therapeutics Inc. stock benefit from interest rate changesTop Gaining Low Risk Assets - Newser
12 Oversold NASDAQ Stocks to Buy Now - Insider Monkey
Apogee Therapeutics (APGE) Falls 17%, Positive Trial Results Fail to Impress Investors - MSN
Why Apogee Therapeutics Inc. stock attracts strong analyst attentionLow Risk Stock Strategies - Newser
How Apogee Therapeutics Inc. stock performs during market volatilityStable Growth Stock Picks - Newser
Canaccord Genuity Reiterated a Buy Rating on Apogee Therapeutics (APGE) - Insider Monkey
Analysts Set Apogee Therapeutics Inc. (NASDAQ:APGE) Price Target at $99.00 - Defense World
Rx Rundown: Merck, Gilead Sciences, Apogee Therapeutics and more - Medical Marketing and Media
Stifel reiterates Buy rating on Apogee Therapeutics stock amid positive AD data - Investing.com Nigeria
Trend Tracker for (APGE) - news.stocktradersdaily.com
Apogee falls after results from atopic dermatitis trial - MSN
Canaccord Genuity reaffirms Buy rating on Apogee Therapeutics stock after positive trial data - Investing.com Canada
Apogee Therapeutics: Funding Supports Best-In-Class Ambitions In Atopic Dermatitis (APGE) - Seeking Alpha
Finanzdaten der Apogee Therapeutics Inc-Aktie (APGE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Apogee Therapeutics Inc-Aktie (APGE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Dambkowski Carl | Chief Medical Officer |
Jul 02 '25 |
Sale |
45.09 |
10,090 |
454,954 |
238,998 |
1.09%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):